Table 2.
Initial laboratory data, disease course, and follow-up for individual patients
| Patient | Age/sex | Uveitis location | Laboratory data | Renal biopsy | Mandeville criteria | Oral steroids | Follow-up (months) | Disease duration (months) | Remission | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ANA | ANCA | ACE | HLA-B27 | RF | Lyme | Syphilis | Initial Uβ2M (μg/L) | Elevated SCr | UA protein | |||||||||
| 1 | 12/M | A | − | – | – | – | – | – | – | 2557 | + | + | + | D | + | 74 | 51.5 | + |
| 2 | 14/M | A | + | – | – | – | – | N | – | 6745 | + | – | + | D | + | 7.7 | 7.7 | – |
| 3 | 15/M | A | – | – | – | – | – | – | – | 1711 | – | – | – | P | + | 41.4 | 18 | + |
| 4 | 16/M | A | − | – | – | – | – | – | – | 3093 | – | – | – | P | + | 26.3 | 26.3 | – |
| 5 | 18/F | P | – | – | – | N | N | – | – | 3169 | + | + | – | P | + | 28.1 | 13.3 | + |
| 6 | 42/F | I | − | – | – | – | – | – | N | 13,669 | + | + | + | D | + | 17 | 17 | – |
| 7 | 53/F | A | – | – | N | – | – | – | 17,494 | + | ++ | – | D | + | 72.4 | 31.3 | + | |
| 8 | 64/F | A | – | – | – | N | N | N | – | 833 | + | – | – | P | – | 2.5 | 2.5 | – |
| 9 | 67/F | I | – | – | – | – | – | – | – | 9557 | + | + | – | P | + | 59.8 | 46.7 | + |
ANA antinuclear antibody, ANCA antineutrophil antibody, ACE angiotensin-converting enzyme, RF rheumatoid factor, Uβ2M urine β-2 microglobulin, SCr serum creatinine, UA urinalysis, F female, M male, A anterior uveitis, I intermediate uveitis, P panuveitis, N not performed, D definite, P probable; + = trace protein on UA; ++ = 1+ protein on UA